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Abstract
Background: Extrapancreatic tissues such as liver may serve as potential sources of tissue for generating insulin-producing
cells. The dynamics of insulin gene promoter activity in extrapancreatic tissues may be monitored in vivo by
bioluminescence-imaging (BLI) of transgenic mice Tg(RIP-luc) expressing the firefly luciferase (luc) under a rat-insulin
gene promoter (RIP).
Methods: The Tg(RIP-luc) mice were made diabetic by a single injection of the pancreatic b-cell toxin streptozotocin.
Control mice were treated with saline. Mice were subject to serum glucose measurement and bioluminescence imaging
daily. On day eight of the treatment, mice were sacrificed and tissues harvested for quantitative luciferase activity
measurement, luciferase protein cellular localization, and insulin gene expression analysis.
Results: Streptozotocin-induced diabetic Tg(RIP-luc) mice demonstrated a dramatic decline in the BLI signal intensity in the
pancreas and a concomitant progressive increase in the signal intensity in the liver. An average of 5.7 fold increase in the
liver signal intensity was detected in the mice that were exposed to hyperglycemia for 8 days. Ex vivo quantitative assays
demonstrated a 34-fold induction of the enzyme activity in the liver of streptozotocin-treated mice compared to that of the
buffer-treated controls. Luciferase-positive cells with oval-cell-like morphology were detected by immunohistochemistry in
the liver samples of diabetic mice, but not in that of non-treated control transgenic mice. Gene expression analyses of liver
RNA confirmed an elevated expression of insulin genes in the liver tissue exposed to hyperglycemia.
Conclusions: BLI is a sensitive method for monitoring insulin gene expression in extrapancreatic tissues in vivo. The BLI
system may be used for in vivo screening of biological events or pharmacologic activators that have the potential of
stimulating the generation of extrapancreatic insulin-producing cells.
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Introduction
The insulin gene is normally expressed in pancreatic b-cells
through specific transcriptional control mechanisms [1,2]. A
highly conserved region approximately 400 bp immediately
upstream of the transcription initiation start site confers both
tissue-specific expression and metabolic regulation of the insulin
gene [3]. Many transcription factors act upon this region forming
a highly sophisticated transcriptional network that ensures precise
regulation. Glucose is the major physiologic regulator of insulin
gene expression; it coordinately controls the recruitment of
transcription factors (e.g., pancreatic/duodenal homeobox-1,
mammalian homologue of avian MafA/L-Maf, Beta2/Neuro D),
the rate of transcription, and the stability of insulin mRNA [4].
Interestingly, it has been recently observed that hyperglycemia,
with or without overt diabetes, activates insulin gene transcription
and proinsulin production in multiple extrapancreatic tissues
including liver, spleen, adipose tissue, thymus and bone marrow
[5]. Hyperglycemia produced by glucose injections in mice led to
the appearance of proinsulin- and insulin-positive cells in the liver
within 3 days. Liver injuries such as those caused by chemical
treatments [6,7] were reported to induce activation and differen-
tiation of hepatic oval cells to insulin-positive cells. Several lines of
evidence [8,9,10,11] also revealed that viral-vector mediated
ectopic expression of pancreatic transcription and differentiation
factors can induce liver cells to express insulin and cure diabetes in
mice. Recently, it was reported [12] that adenoviral vector-
mediated expression of transcription factor Neurogenin3 (NGN3)
in liver resulted in a sustain expression of insulin in neo- islets cells
derived most likely from the hepatic progenitor oval cells that
secrete insulin in a glucose-responsive manner, stably reversing the
hyperglycemia. The surprising capacity of the mature liver to serve
as a potential source of tissue for generating functional insulin-
producing cells provides a potential strategy for the treatment of
diabetes.
In this study, we aim to establish an animal model to monitor
insulin gene expression in extrapanceatic tissues in vivo and
characterize the time-course of the insulin promoter activation in
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(BLI) [13,14]. To do this, we induced hyperglycemia by
streptozotocin (STZ) treatment in transgenic mice that express
the firefly luciferase under the regulation of the 760 bp rat-insulin
gene I-promoter. Rodents have two nonallelic insulin genes,
insulin I and insulin II [15]. The insulin I gene is expressed in
pancreatic beta cells and scattered cells in the thymus [16]. The
insulin II gene, which is the ancestral gene and the homolog of the
human gene, is expressed in pancreatic beta cells, and in the
choroid plexus (secreting epithelium) region of the brain [17]. The
expression pattern of luciferase in the transgenic mice used in this
study was therefore expected to be similar to that of the
endogenous insulin II gene. As a novel approach, BLI was used
to monitor in real-time and to semi-quantify luciferase expression
in the control and the STZ-treated diabetic mice in vivo.I n
addition, luciferase expression in the liver samples from the mice
was examined by quantitative measurement of the enzyme activity
ex vivo, and by immunohistochemistry to identify cells expressing
the enzyme. To confirm that the transgene expression mimics that
of the endogenous insulin gene, insulin gene expression in the liver
was examined by semiquantitative Reverse Transcription (RT)-
PCR analyses in autopsy liver samples.
Materials and Methods
Mice
A transgenic mouse line, FVB/N-Tg(RIP-luc) containing the
firefly luciferase gene under the regulation of the rat insulin
promoter II (RIP, 760 bp) that specifically and constitutively
expresses firefly luciferase in the pancreatic islet b-cells (Caliper
Life Sciences, Alameda, CA), was used for both experimental and
control groups. All mice were housed in a barrier facility at
Northwestern University and were used at ages 3-4 months. All
animal procedures were approved by the Animal Care and Use
Committee at Northwestern University.
Diabetes Induction
FVB/N-Tg(RIP-luc) mice were made diabetic by a single
intraperitoneal (i.p.) injection of the pancreatic b-cell toxin
streptozotocin (STZ, 220 mg/kg body weight dissolved in saline,
Sigma-Aldrich, St. Louis, MO). Serum glucose levels were
measured daily using a glucometer (One Touch Basic, Lifescan
Inc., Milpitas, CA). Mice that demonstrated serum glucose levels
greater than 300 mg/dL on two consecutive days were considered
diabetic. Control mice received an i.p. injection of saline solution.
In Vivo Bioluminescence Imaging
In preparation for BLI, control and diabetic FVB/N-Tg(RIP-
luc) mice were anesthetized with 2.5% isofluorane in air. Substrate
luciferin potassium salt (Molecular Therapeutics Inc., Ann Arbor,
MI) dissolved in PBS (40 mg/ml) was administered via a single i.p.
injection at a dose of 200 mg/kg body weight. The mice were
placed in the camera chamber, where a controlled flow of 2.0%
isofluorane in air was administered through a nosecone via a gas
anesthesia system designed to work in conjunction with the BLI
system (IVISH 200, Caliper Life Sciences). Mice were imaged for
one-minute durations on both the dorsal and ventral sides at
medium-resolution with a field of view of 20 cm at 10 minutes post
luciferin injection. A gray-scale body image was collected and
overlaid by a pseudo-color image representing the spatial
distribution of detected photons. The BLI signal intensities emitted
from the liver region of the mice were quantified using a fixed
region of interest (ROI) of 261.5 cm in size from dorsal images
and expressed as photons per second of light. Background images
were collected daily and background subtractions were automat-
ically calculated by the Living Image software. Ventral images
were collected solely for visual purposes.
Quantitative Luciferase and Total Protein Measurements
Autopsy mouse liver tissue samples were collected from either
control normal glycemic mice or mice that had been treated with
STZ and exposed to hyperglycemia for 8 days. The randomly
collected liver samples (,5m m
2) were placed in 400 ml of Passive
Lysis Buffer (Promega Corp, Madison, WI) and were homoge-
nized using a handheld tissue homogenizer (Pellet PestleH Motor,
Kontes). Tissue homogenates were centrifuged and the superna-
tant were used for luciferase activity and protein concentration
assays. For the luciferase activity measurement, the In Vitro
Luciferase Assay System (Promega) was used according to
instructions provided by the manufacturer. Tissue homogenates
(20 ml) and the luciferase substrate (100 ml) were mixed and the
luminescence generated from the reaction was measured using a
Sirius Luminomter (Berthold Detection Systems). Background
luminescent readings were obtained and were subtracted from the
luminescent data. Protein concentrations were determined using
the BCA Protein Assay Kit (Pierce, Rockford, IL) according to the
manufacturer’s protocol and analyzed using a CoultarH UV Max
microplate reader and the associated Softmax Pro version 3.1.2
software (Molecular Devices, Sunnyvale, CA). The luminescence
of each of the sample lysates was calculated and expressed as
relative light units (RLU) per second per microgram of protein.
Tissue Preparation, Antibodies, and
Immunohistochemical Analysis
Autopsy mouse pancreas and liver tissue samples were collected
from Tg(RIP-luc) mice that were either control normoglycemic or
that had been treated with STZ and exposed to hyperglycemia for
8 days. The samples were fixed in 10% buffered-formalin for
48 hours prior to paraffin embedding. Tissue sections of 3,4
microns were cut and placed on charged slides, allowed to air dry
before placing in a 60uC oven for at least 1 hour for adhesion.
After deparaffinization and antigen retrieval, the tissue sections
were incubated with primary rabbit polyclonal antibody to Firefly
Luciferase (Abcam Inc, Cat#ab21176, 1:500) for 30 min at room
temperature, followed by incubation with a ready-to-use En-
Vision
TM+ Single Reagents (Dako, Cat#K4003) for 15 min at
room temperature. Images of the graft sections were acquired
using a Zeiss fluorescence axial microscope attached with a digital
camera.
RNA Extraction and Analysis of Tissue mRNA Expression
Total RNA was prepared from frozen liver samples using TRI
Reagent (Molecular Research Center) with bromochloropropane
according to the manufacturer’s protocol. RNA quantity and
quality was determined spectrophotometrically and 0.7 mg total
RNA was used for reverse transcription in the presence of
MMLV-Reverse Transcriptase and random hexanucleotides
(Promega). The reverse-transcribed samples were denatured and
amplified by PCR in the presence of GoTaq Flexi DNA
Polymerase (Promega) in a PCR System 6700 (Applied Biosys-
tems) for over 30 cycles (94uC, 45 sec; 58.5uC, 45 sec; 72uC,
45 sec) with a final extension time (72uC, 4 min). A sham reaction
without the reverse transcriptase was performed in order to ensure
that PCR amplification did not arise from genomic DNA
contamination. PCR primers used for the detection of insulin-I
were: forward 59-ccatcagcaagcaggtca-39; reverse 59-ccacacaccagg-
tagagagc-39; insulin-II: forward 59-cctgctggccctgctctt-39 and re-
A Real Time Approach
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separated by electrophoresis in 1.8% agarose stained with
ethidium bromide. All reaction templates were normalized using
the same PCR conditions with GAPDH expression using primers:
forward 59-accacagtccatgccatcac-39 and reverse 59-tccaccaccctgt-
tgctgta-39.
Data Analysis
The mean 6 standard error (SE) of the BLI signal intensity and
luminescence for both groups were calculated and the unpaired
two-tailed Student’s t-test was used for statistical analysis. A
probability (p) value of ,0.05 was considered to be statistically
significant.
Results
In Vivo Bioluminescence Imaging and Luciferase
Expression
Mouse serum glucose levels and luciferase expression in the liver
were evaluated daily for 8-10 days following treatment with saline
solution (Control, n=6) or STZ (n=6). Figures 1A and 1B show
the ventral and dorsal bioluminescence images of a representative
control mouse taken on days 0, 4 and 8 after the start of the
experiment. The blood glucose reading and the BLI signal
intensity of the circular area (ROI, the liver region of interest) were
recorded under each image. As expected, strong and consistent
levels of BLI signals were detected from the pancreas region on all
days tested as the serum blood glucose level stabled. The strongest
signal was detected from the tail-portion of the pancreas while the
head of the pancreas can be more clearly visualized from the
dorsal side. The BLI signal intensity from the liver ROI was near
the background reading (8.0,9.0610
4 photons/second) at all
times tested.
In comparison, Figures 1C and 1D represent the luminescence
imaging of a STZ-treated FVB/N-Tg(RIP-luc) mouse in ventral
and dorsal positions on days 0, 2, 4, 6, and 8 as serum blood
glucose levels increased over a period of eight days. As
demonstrated by Figure 1C, there was a dramatic decrease in
pancreatic luminescent signal soon after the STZ treatment as the
b-cell function was lost, and a concomitant spatial shift of the
luminescent intensity to the area where liver is located as serum
blood glucose levels rose above 300 mg/dl. The location where
the luminescence was detected was very similar to that of
luminescence emitted from non-transgenic FVB/NJ mice trans-
planted with the luciferase-tagged islets in the liver [13]. The shift
of luminescent expression also occurred on the dorsal side of the
mouse as shown in Figure 1D. To quantify the changes in
bioluminescence intensity, a fixed circle (ROI) was placed over the
area of the upper right abdomen on the dorsal side as shown in the
figures. This specific area of the liver was targeted because of its
distant proximity from the pancreas, thus minimizing pancreatic
signal interference. As shown in Figure 1D, the BLI signal
obtained from the liver ROI of a representative mouse on day 0
was 8.1610
4 photons/second, similar to that of the controls. The
signal intensity increased 5.43 fold to 4.4610
5 photons/second
over the course of eight days under hyperglycemia. Enhanced
Figure 1. Representative mouse bioluminescence images. Panels A and B are ventral and dorsal bioluminescence images of a representative
control mouse on days 0, 4 and 8 after the start of the experiment. Panels C and D are ventral and dorsal bioluminescence images of a representative
mouse on days 0, 2, 4, 6 and 8 after treatment of STZ. Images were standardized to a light intensity scale on the right. The daily mouse blood glucose
level and the liver ROI luminescent intensity were recorded under each image.
doi:10.1371/journal.pone.0009397.g001
A Real Time Approach
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9397luminescence was detected by BLI in the liver region as early as
24 hours following treatment with STZ when the blood glucose
level rose near or above 200 mg/dl (data not shown).
We also observed enhanced luminescence signal on the left side
of the mouse (Figure 1D) with the progression of hyperglycemia.
The location and the shape of the BLI images suggested that it was
emitted from the spleen. The spleen is one of the organs that
demonstrated positive insulin gene expression under diabetic
conditions [5]. In addition, some of the STZ-treated mice showed
an enhanced luminescence signal from the brain area as detected
by BLI (data not shown). As discussed above, brain tissue is known
to be an active site for insulin II gene.
Figure 2A summarizes the average serum glucose levels from
both the saline- and the STZ-treated mice on days 2, 4, 6, and 8
following treatment. As shown, the average serum glucose levels
on day 0 for the control and treatment groups were 126611.7 and
123615.4 mg/dl respectively (p=0.81). While the saline-treated
control mice maintained normoglycemia during the entire study
period, the STZ-treated mice had a progressive increase in the
blood glucose level each day thereafter (230614, 295614,
329616, and 334615 mg/dl, respectively), resulting in a
significant difference from that of the control mice on days 2, 4,
6 and 8 (p=0.002, 2.98610
25, 4.49610
26 and 1.25610
26
respectively). Moreover, the average serum glucose level of the
STZ-treated mice on day 0 before treatment was significantly
different from that of days 2, 4, 6 and 8 (p,0.001 for all time
points).
With the increase in the blood glucose level, there was a
significant increase in luciferase expression in the liver of STZ-
treatedmice. Figure 2B represents the quantified averageBLIsignal
intensity from the mouse liver region on days 0, 2, 4, 6, and 8
following treatment with saline or STZ. The BLI signal of the liver
was quantified from the fixed ROI on the dorsal image as
demonstrated in Figures 1B and 1D. The mean (6 SE) BLI
intensities on day 0 for the control and treated mice were
8.5660.02610
4 and 11.1060.04610
4 photons/second respective-
ly. No statistical differences between the groups were found
(p=0.55). The signal intensity from the liver area of STZ-treated
mice increased significantly each day thereafter (23.3060.66610
4,
47.061.85610
4, 58.562.30610
4 and 62.6062.19610
4 photons/
second respectively), resulting in a statistical difference from the
control mice on days 2, 4, 6, and 8 (p=0.044, 0.046, 0.012, and
0.031 respectively). An average of 5.64 fold increase in the liver
signal intensity was detected in the mice that were exposed to
hyperglycemiafor8 days. The averageBLIof the STZ-treatedmice
on day 0 before treatment was statistically different from days 2, 4,
6,and 8 (p=0.03,0.0003, 0.0001,and0.0002respectively),whereas
no significant differences were observed in the control mice.
Ex Vivo Luciferase Enzyme Activity Measurement
To confirm the in vivoBLIfinding that luciferaseexpression under
the insulin promoter was elevated in the liver under hyperglycemia,
liver autopsy samples were obtained on day 8 and luciferase assays
were performed on tissue lysates from the liver to quantify the
luciferase expression in control and treated mice. A total of 14
random control samples and 35 random STZ-samples from 6 mice
in each group were analyzed. Figure 3 represents the mean (6 SE)
luciferase activity expressed in RLU per gram of protein. As shown
Figure 2. Quantified average mouse blood glucose level and BLI signal intensity from the mouse liver region. Panels A and B are
average measurements of, respectively, non-fasting blood glucose and BLI signal intensity from the liver ROI of the control saline-treated mice (n=6)
and diabetic STZ-treated mice (n=6). ‘‘*’’ indicates a significant difference between the measurements of the STZ-treated mice and that of the control
mice on the same time point.
doi:10.1371/journal.pone.0009397.g002
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0.3060.03610
9 whereas the luciferase activity for the hyperglyce-
mia-liver produced an average of 10.0060.10610
9. There was a
34-fold induction in the luciferase activity in the liver after an eight-
day exposure to hyperglycemia with a very large statistical
difference (p=6.76610
210) compared to that of the controls.
Luciferase activity in the brain tissue homogenate was also
measured, quantified and shown to be 2-fold higher in the STZ-
treated mice than that of the controls (data not shown).
Immunohistochemical Staining of Cells Expressing
Luciferase
For the identification of cells expressing luciferase, liver tissue
samples from the Tg(RIP-luc) mice, both diabetic and non-treated,
were subject to immunohistochemical staining with an anti-
luciferse antibody. As shown in Figure 4, luciferase-positive cells
were detected in the liver samples from the STZ-induced diabetic
mice, but not in the liver samples of the non-treated control
transgenic mice. These cells are likely hepatic oval cells since they
are small in size (approximately 10 mm), with a large nucleus-to-
cytoplasm ratio and an oval-shaped nucleus, and are located in the
periportal region of the liver. No hepatocytes were detected
positive for luciferase expression. In the pancreas samples of the
Tg(RIP-luc) mice, luciferase-positive cells were only detected in
islets (data not shown).
Liver Insulin Gene Expression Analyses
To determine if the transgene expression detected by BLI was
associated with the endogenous insulin gene promoter activity, the
expression of insulin-I and insulin-II were examined by semi-
quantitative RT-PCR analysis of RNA samples prepared from the
liver samples of control and STZ-treated mice. As shown in
Figure 5, the expression of both the endogenous insulin-I and
insulin-II genes were elevated in the liver RNA samples from
animals exposed to hyperglycemia for 8 days (samples 3, 4, and 5).
No insulin transcripts were detected in the control liver samples
(samples 1 and 2).
Discussion
With Type I diabetes, and in some patients with Type II
diabetes, the lack of insulin can best be supplemented by providing
new insulin-producing cells. Potential alternative approaches for
obtaining more insulin producing cells for the treatment of
diabetes include proliferation of existing b-cells, differentiation
from adult endocrine progenitor cells or embryonic stem cells, and
reprogramming of non-b-cells such as acinar or liver cells to b-cells
[18]. Each of these approaches has distinct merits and limitations,
and are at the early stages of investigation and development.
As the above mentioned approaches of obtaining more insulin-
producing cells from b- or non-b-cell origins are being
investigated, the ability to observe, locate and quantify the cells
producing insulin over time in vivo in real time, has become
increasingly important. In this study, we sought to validate the use
of a non-invasive in vivo imaging system for the detection of
induction of non islet-b cells such as liver cells to insulin-producing
cells. The induction model used in this study has been reported
previously [5,6,7]. The novelty of our investigation lies in the
application of BLI to the model in which the transgenic mice
expressing the reporter gene coding for the firefly-luciferase driven
by a rat insulin gene promoter were treated with STZ to induce
hyperglycemia, a condition known to induce the insulin gene
expression in liver cells. We demonstrated that BLI allows the
detection of activation of insulin gene in vivo via reporter luciferase
expression in a timely and semi-quantitative manner. In addition,
the activation site (organ) can be visualized and identified.
Non-invasive in vivo imaging can provide real-time spatial and
temporal information about the location, function, and viability of
cells of interest in intact living animals. The luciferase reporter
Figure 3. Quantified liver luciferase enzyme activity ex vivo. The
firefly luciferase enzyme activity was measured in the liver samples from
the control (n=14) and the STZ-treated (n=35) mice. The enzyme
activity is expressed as the relative light unit (RLU) detected per gram of
protein.
doi:10.1371/journal.pone.0009397.g003
Figure 4. Representative images of mouse liver sections
stained for luciferase. Control and diabetic Tg(RIP-luc) mouse liver
samples were stained by the immunoperoxidase technique for firefly
luciferase. Scales represent the original magnification.
doi:10.1371/journal.pone.0009397.g004
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expression in animals. This molecular imaging strategy has been
effectively incorporated into studies of small animal models of
human biology and disease [19,20]. The tool offers the advantage
of noninvasive in vivo assessment of the molecular and cellular
events that are often targets of therapy; as such, these events can
be studied in individual animals over time. This reduces the
number of animals required for a given study and improves the
quality of the data set, as the temporal measurement allows for
each animal to serve as its own control. As have been reported in
our previous studies using BLI to monitor islets after transplan-
tation, BLI is a sensitive method for monitoring gene expression in
minimal amounts of cells as it is capable of detecting as few as 10
luciferase-expressing islets transplanted to the liver via portal vein
infusion [14]. Nonetheless, the measurement of luciferase activity
in vivo is challenged by the fact that light transmission is subjected
to attenuation by tissues overlaying the light source in live animals.
In this study, we observed luminescence from liver, brain (not
shown), and possibly spleen of mice under hyperglycemia. This
does not exclude the possibility that the insulin genes in other
tissues such as adipose and bone marrow are also activated, as
reported by others [5]. Rather, it suggests that the level of insulin
gene expression in these other tissues may be, if present, lower
than that in the liver and beyond the detection limit of the imaging
modality. It has been reported that hepatic oval cells, the liver
progenitor cells, can be activated and differentiated toward
pancreatic beta-cell phenotype under conditions such as high
concentrations of glucose, liver injury (e.g. STZ-treatment) or
NGN3 overexpression [6,7,12,21]. Consistent with these reports,
the immunohistochemical staining results in this study showed
that, under the experimental condition, luciferase expression
driven by the rat insulin promoter was mainly activated in cells
with oval cell morphology.
In conclusion, BLI is a valid, sensitive, and semi-quantitative
technology for monitoring insulin gene expression when used in
combination with transgenic mice expressing reporter gene
luciferase under the regulation of the insulin gene promoter. It
may be used for in vivo screening of pharmaceutical drugs that have
the potential of stimulating the generation of new sources of
insulin-producing cells in aspects previously inaccessible to
investigation.
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